|
| 34110392 | Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019. | JAMA Netw Open | 2021 |
| 32220910 | Use of intravenous magnesium sulfate among patients with acute myocardial infarction in China from 2001 to 2015: China PEACE-Retrospective AMI Study. | BMJ Open | 2020 |
| 32315070 | Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. | JAMA Netw Open | 2020 |
| 31658831 | Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center. | Circ Heart Fail | 2019 |
| 28929484 | Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study. | Int J Cancer | 2018 |
| 30646146 | Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia: An Analysis of Within- and Between-Hospital Variation. | JAMA Netw Open | 2018 |
| 30380383 | Complements from the Lung. | N Engl J Med | 2018 |
| 29377075 | Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis. | Clin Pharmacol Ther | 2018 |
| 29215916 | New and incremental FDA black box warnings from 2008 to 2015. | Expert Opin Drug Saf | 2018 |
| 28657868 | Regulatory Review of New Therapeutic Agents. | N Engl J Med | 2017 |
| 28379798 | Regulatory Review of New Therapeutic Agents - FDA versus EMA, 2011-2015. | N Engl J Med | 2017 |
| 28468750 | Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. | BMJ | 2017 |
| 28345539 | Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes: A Cross-sectional Study. | Chin Med J (Engl) | 2017 |
| 28179418 | Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study. | BMJ Open | 2017 |
| 28093943 | Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014. | Otolaryngol Head Neck Surg | 2017 |
| 28116974 | Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014. | Otolaryngol Head Neck Surg | 2017 |
| 28492899 | Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. | JAMA | 2017 |
| 29158421 | Urban-Rural Comparisons in Hospital Admission, Treatments, and Outcomes for ST-Segment-Elevation Myocardial Infarction in China From 2001 to 2011: A Retrospective Analysis From the China PEACE Study (Patient-Centered Evaluative Assessment of Cardiac Events). | Circ Cardiovasc Qual Outcomes | 2017 |
| 29273664 | Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study. | BMJ Open | 2017 |
| 28950309 | Are non-ST-segment elevation myocardial infarctions missing in China? | Eur Heart J Qual Care Clin Outcomes | 2017 |
| 28975302 | Characteristics of Novel Therapeutics and Postmarket Safety Events-Reply. | JAMA | 2017 |
| 28645937 | Quality of Care in Chinese Hospitals: Processes and Outcomes After ST-segment Elevation Myocardial Infarction. | J Am Heart Assoc | 2017 |
| 28927183 | Ischaemic heart disease in China: the time to address rising mortality rates. | Eur Heart J Qual Care Clin Outcomes | 2017 |
| 28662045 | Describing the performance of U.S. hospitals by applying big data analytics. | PLoS One | 2017 |
| 26945565 | The china patient-centered evaluative assessment of cardiac events (PEACE) prospective study of percutaneous coronary intervention: Study design. | Catheter Cardiovasc Interv | 2016 |
| 28263938 | Analysis of Machine Learning Techniques for Heart Failure Readmissions. | Circ Cardiovasc Qual Outcomes | 2016 |
| 26554874 | Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study. | Pharmacoepidemiol Drug Saf | 2016 |
| 27428055 | Generic Drug Approvals Since the 1984 Hatch-Waxman Act. | JAMA Intern Med | 2016 |
| 26712436 | China Patient-centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction: Study Design. | Chin Med J (Engl) | 2016 |
| 27058862 | National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011. | PLoS One | 2016 |
| 26974883 | Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI Study. | JAMA Intern Med | 2016 |
| 26729395 | Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Million Persons Project pilot. | BMJ Open | 2016 |
| 27079511 | Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals. | Trials | 2016 |
| 25808713 | Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study. | Br J Clin Pharmacol | 2015 |
| 26435528 | Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation. | Nat Rev Drug Discov | 2015 |
| 26656011 | Qingdao Port Cardiovascular Health Study: a prospective cohort study. | BMJ Open | 2015 |
| 26689591 | Organizational culture in cardiovascular care in Chinese hospitals: a descriptive cross-sectional study. | BMC Health Serv Res | 2015 |
| 26071031 | National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011. | J Am Heart Assoc | 2015 |
| 26219053 | Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013. | JAMA | 2015 |
| 25847652 | Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugs. | Health Aff (Millwood) | 2015 |
| 25664529 | Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right? | JAMA Intern Med | 2015 |
| 24474248 | Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service. | JAMA | 2014 |
| 25387775 | Managing the information boundary of an organization: key aspect of translating research into practice. | Circ Cardiovasc Qual Outcomes | 2014 |
| 25333986 | Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison. | PLoS One | 2014 |
| 25070357 | Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional study. | JAMA Intern Med | 2014 |
| 24796406 | Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis. | JAMA Intern Med | 2014 |
| 24867021 | Trial evidence and approval of therapeutic agents--reply. | JAMA | 2014 |
| 24938574 | Withdrawal of Personal Genome Service--reply. | JAMA | 2014 |
| 24449315 | Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. | JAMA | 2014 |
| 22591257 | Regulatory review of novel therapeutics--comparison of three regulatory agencies. | N Engl J Med | 2012 |